Low Frequency of PIK3CA Gene Mutations in Hepatocellular Carcinoma in Chinese Population
Tóm tắt
PI3K/AKT constitutes an important pathway regulating the signaling of multiple biological processes and plays a critical role in carcinogenesis. PIK3CA gene missense mutations have been reported in many human cancer types. The mutation of it in hepatocellular carcinoma cases varies with different races and regions. In this study, we investigated PIK3CA mutation in Chinese hepatocellular carcinoma patients. A total 90 Chinese patients of hepatocellular carcinoma were recruited in this study. Exons 9 and 20 hotspots mutations of PIK3CA gene were detected by PCR-based DNA sequencing. Two point mutations (E542K and D549H) in exon 9 were found in only one patient (1/90; 1.11%), no mutation was found in exon 20 in any cases. 57 patients are associated with HBV infection (57/90; 63.3%), and 8 patients with HCV infection (8/90; 8.9%). The frequency of the PIK3CA mutations in hepatocellular carcinoma seems to be lower in Chinese hepatocellular carcinoma patients. These findings suggest that PI3K mutations may not play a major role in hepatic carcinogenesis in Chinese. HBV infection has close relationship with HCC in Chinese.
Tài liệu tham khảo
Parkin DM, Whelan SL, Ferlay J, et al (2005) Cancer incidence in five continents, Vols. I to VIII (IARC Cancer Base). International Agency for Research on Cancer
Zhang JY, Dai M, Wang X et al (1998) A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan. China Int J Epidemiol 27:574–578
Osaki M, Oshimura M, Ito H (2004) PI3K-Akt pathway: its functions and altertions in human cancer. Apoptosis 9:667–676
Samuels Y, Wang Z, Bardelli A et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 23:554
Yamamoto H, Shigematsu H, Nomura M et al (2008) PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 68:6913–6921
Okudela K, Suzuki M, Kageyama S et al (2007) PIK3CA mutation and amplification in human lung cancer. Pathol Int 57:664–671
Souglakos J, Philips J, Wang R et al (2009) Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 101:465–472
Sartore-Bianchi A, Martini M, Molinari F et al (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69:1851–1857
Phillips WA, Russell SE, Ciavarell ML et al (2006) Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett’s esophagus. Int J Cancer 118:2644–2646
Mori R, Ishiguro H, Kimura M et al (2008) PIK3CA mutation status in Japanese esophageal squamous cell carcinoma. J Surg Res 145:320–326
Kalinsky K, Jacks LM, Heguy A et al (2009) PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15:5049–5059
Stemke-Hale K, Gonzalez-Angulo AM, Lluch A et al (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68:6084–6091
Velho S, Oliveira C, Ferreira A et al (2005) The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 41:1649–1654
Vivian L, Chi W, Tsun C et al (2005) Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 5:29–34
Kuo KT, Mao TL, Jones S et al (2009) Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174:1597–1601
Jehad A, Prashant B, Wael AH et al (2009) PIK3CA alterations in Middle Eastern ovarian cancers. Mol Cancer 8:51–53
Lee JW, Soung YH, Kim SY et al (2005) PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24:1477–1480
Boyault S, Rickman DS, Reynies A et al (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45:42–52
Riener M, Bawohl M, Clavien PA et al (2008) Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosome Canc 47:363–367
Tanaka Y, Kanai F, Tada M et al (2006) Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene 25:2950–2952
Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338
Kang S, Bader AG, Vogt PK (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102:802–807
Ikenoue T, Kanai F, Hikiba Y et al (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65:4562–4567
Liu Z, Roberts TM (2006) Human tumor mutants in the p110 subunit of PI3K. Cell Cycle 5:675–677
Gymnopoulos M, Elsliger MA, Vogt PK (2007) Rare cancer-specific mutations in PIK3CA show gain of function. PNAS 104:5569–5574
Mohandas KM (2004) Hepatitis B associated hepatocellular carcinoma: epidemiology, diagnosis and treatment. Hep B Annual 1:140–152
Russo MW, Jacobson IM (2002) Hepatocellular cancer: screening, surveillance, and prevention. In: Kelsen DP, Daly JM, Kern SE et al (eds) Gastrointestinal oncology: principles and practices. Lippincott, Williams and Wilkins, Philadelphia, pp 559–568
Sun Z, Ming L, Zhu X et al (2002) Prevention and control of hepatitis B in China. J Med Virol 67:447–450